Organoid biobanks as a new tool for pre-clinical validation of candidate drug efficacy and safety

Gerardo Botti; Maurizio Di Bonito; Monica Cantile

Organoid biobanks as a new tool for pre-clinical validation of candidate drug efficacy and safety

Int J Physiol Pathophysiol Pharmacol. 2021 Feb 15;13(1):17-21. eCollection 2021.

Authors

Gerardo Botti¹, Maurizio Di Bonito², Monica Cantile²

Affiliations

¹ Scientific Direction, Istituto Nazionale Tumori-Irccs-Fondazione G. Pascale Naples, Italy.
² Pathology Unit, Istituto Nazionale Tumori-Irccs-Fondazione G. Pascale Naples, Italy.

PMID: 33815668
PMCID: PMC8012858

Abstract

The growing need for personalized medicine for cancer patients has enhanced and optimized the production of living tumor organoids that have become optimal preclinical models for the discovery and screening of anticancer drugs. The systematic collection and storage of tumor organoids through the establishment of dedicated biobanks will represent a fundamental tool for cancer research and clinical trials.

Keywords: Organoids; biobank; precision medicine.